Donafenib for Recurrent Cervical Cancer

Inclusion criteria

* Written informed consent obtained.
* Age 18\~75, female.
* Histologically confirmed cervical squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma.
* Patients with cervical cancer recurred for the first time, and did not receive any treatment after recurrence.
* Patients must have measurable disease per RECIST 1.1.
* ECOG performance status 0 or 1, expected lifetime ≥ 3 months.
* No targeted drugs containing VEGF were used before, including but not limited to anlotinib, apatinib, bevacizumab, etc.
* Adequate organ function:
* Absolute neutrophil count (ANC) ≥ 1.5x109/L, Platelets ≥ 100x109/L, Hemoglobin (Hb) ≥ 90g/L, Bilirubin ≤ 1.5 times the upper limit of normal, ALT/AST ≤ 3x ULN (for patient with liver metastasis ALT/AST ≤ 5x ULN), Serum bilirubin ≤1.5x ULN, Serum creatinine ≤ 1.5 times the upper limit of normal, and creatinine clearance ≥ 40ml/min (calculated by Cockcroft-Gault formula); International normalized ratio (INR) ≤1.5

Exclusion Criteria:

* Histopathologic diagnoses of tumors other than squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma.
* With second primary malignant diseases.
* Pregnancy or children bearing potential.
* With uncontrolled auto-immune diseases, interstitial pneumonia, ulcerative colitis, or patients who should receive long-term glucocorticoid treatment (\>10mg/d prednisone).
* With uncontrollable complications.
* Conditions which impact on pill taking (dysphagia, chronic diarrhea, bowel obstruction).
* Known hypersensitivity reaction to any of the study drugs or components.
* Other unsuitable conditions determined by investigators.
* Hepatitis B virus (HBV) \>2000 IU/ml or DNA ≥ 1×10\^4/ml; or hepatitis C virus (HCV) RNA ≥ 1×10\^3/ml).
* Has received a live vaccine within 4 weeks prior to the first dose of trial treatment. Note: Injection of inactivated viral vaccines against seasonal influenza are allowed.
* Has pleural effusion and ascites that require punctured and drained. However, an exception includes patients with pleural effusion and ascites who have no symptoms.
* Any other medical, psychiatric, or social condition deemed by the investigator to be likely to interfere with a subject's rights, safety, welfare, or ability to sign informed consent, cooperate, and participate in the study or would interfere with the interpretation of the results.